ImmunityBio faces securities class action after FDA flags misleading promotions; shares fall 21%

ImmunityBio Inc

ImmunityBio Inc

IBRX

0.00
  • Securities class action filed over alleged false or misleading promotional communications flagged by FDA, covering investors who bought securities from Jan. 19, 2026 to Mar. 24, 2026.
  • Shares fell $1.98, or 21%, following FDA determination cited in complaint.
  • Investors seeking lead plaintiff role must file motion by May 26, 2026; case filed in U.S. District Court for Central District of California.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605070900PR_NEWS_USPR_____NY53577) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.